A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma

Article Information

DOI 
http://dx.doi.org/10.1177/155989770700700305
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2007 MD Conference Express

Author Information

  1. Lori Alexander
  1. Bernard Escudier, MD
    1. Institut Gustave Roussy, Paris, France
View Full Text

Article usage

AbstractFullPDF
Apr 2015500
May 2015100
Jul 2015011
Aug 2015100
Sep 2015100
Oct 2015232
Nov 2015133
Total1176

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Oncology Clinical Trials
Gastrointestinal Cancers